Management of Atrial Flutter with Diltiazem and Amiodarone

Introduction to Atrial Flutter Management

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend beta blockers, diltiazem, or verapamil as first-line agents for acute rate control in hemodynamically stable atrial flutter patients, with a Class I recommendation and C-LD level of evidence 1, 3, 5, 6
• The American College of Cardiology, American Heart Association, and Heart Rhythm Society give intravenous amiodarone a Class IIa recommendation for acute rate control in atrial flutter, specifically when beta blockers are contraindicated or ineffective, or in patients with systolic heart failure 1, 2, 3, 4, 5

Clinical Considerations for Diltiazem and Amiodarone Use

• Amiodarone has less negative inotropic effect than beta blockers, diltiazem, and verapamil, making it preferred in critically ill patients or those with tenuous hemodynamic stability 1, 2, 3, 4
• The combination of diltiazem and amiodarone may be safer in patients with reduced ejection fraction, as amiodarone has less negative inotropic effect 1, 2, 3
• Achieving adequate rate control in atrial flutter is often more difficult than in atrial fibrillation, and may require higher doses of rate-control agents or combination therapy 1, 6

Important Caveats and Considerations

• If amiodarone converts atrial flutter to sinus rhythm, ensure adequate anticoagulation if the flutter has lasted ≥48 hours, following guidelines that align with those for atrial fibrillation 1, 2, 3, 4
• Amiodarone should not be used for long-term rate control due to potential toxicity, but short-term intravenous use does not carry the same risks 1, 2, 3, 4, 7
• Monitoring for hypotension, excessive bradycardia, and acute kidney injury is crucial when using diltiazem and amiodarone together 1, 3, 6